Genovis’ Board of Directors decides on rights issue

Sales of products from Genovis’ protein engineering portfolio have shown a
steady increase of about 100% percent annually. Genovis aims to maintain this
growth rate during 2013 and thus approach a positive cash flow. Achieving this
goal requires financing of about SEK 7 million. At the same time, because the
Board of Directors at Genovis wishes to increase transparency and clarity when
communicating about developments in the two portfolios, it has decided to
streamline the activities of the parent company.

Consequently, the nano portfolio, which focuses primarily on new contrast agents
intended for both the preclinical and clinical markets, will be placed in the
wholly owned subsidiary GeccoDots AB (formerly Eijdo research AB). Genovis will
raise funds to actively run the subsidiary in 2013. The cost is expected to be
about SEK 6 million and is included in the 2013 budget. The project, which
focuses on both imaging of lymph nodes in tumor diseases and stem cell tracking,
will continue to be carried out to the extent that the subsidiary receives
financing, which is expected through research support and other external
financing.

To achieve the above objectives, the Board has decided to conduct a rights
issue.
Rights issue

With the authorization of the 2012 Annual General Meeting, the Board of
Directors of Genovis has decided to conduct a rights issue to existing
shareholders in which three (3) existing shares entitle the holder to
subscription for one (1) new share at a subscription price of SEK 3.50/share. As
a result of this decision share capital could increase by a maximum of SEK
1,578,075.60 through the issuance of up to 3,945,189 shares. Following the
completed rights issue, share capital will amount to a maximum of SEK
6,312,302.80 and the number of shares to 15,780,757.The Company will raise about
SEK 13.8 million before issue expenses, which are expected to be SEK 600,000.
The issue will have a dilutive effect of 25% on the holdings of those who do not
subscribe for their full stake.

Principal owners Mikael Lönn and LMK Ventures AB have provided written
subscription undertakings and will subscribe for their respective shares of the
issue. In addition, Mikael Lönn and LMK Ventures AB have provided a guarantee
along with subscription commitments guaranteeing 70% of the total issue volume.
Guarantee fees of 5% will be charged on the amount exceeding the sum of the
underwriters’ subscription undertakings. The guarantee fee is SEK 256,141 to be
divided equally between the underwriters.

Timetable for rights issue

March 28, 2013                  Record date for participation in the rights
issue; shareholders registered on this day in the share register maintained by
Euroclear will receive subscription rights for participation in the rights
issue.

April 4-17, 2013                Subscription period. Subscription with
preferential rights through cash payment during the subscription period.
Registration of interest in subscription without preferential rights may be
submitted throughout the subscription period.

Investor meeting

In conjunction with the rights issue, Genovis will hold investor meetings on
three occasions. CEO and founder Sarah Fredriksson, as well as representatives
of Genovis’ management team, will attend all meetings. Information about
investor meetings and registration will be available on the Genovis website.

Preliminary schedule for investor meetings

Lund                April 3

Helsingborg     April 4

Stockholm       April 9
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
4646 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis develops and sells innovative technologies from two unique product
portfolios. The first includes enzymes that facilitate development and quality
control for applications such as antibody-based drugs. The products launched to
date are aimed at customers who work with development of drugs, new diagnostic
methods and basic research.

The second consists of nanotechnology in new contrast agents and focuses on
design, production and characterization of nanostructures as contrast agents in
medical imaging. The nanostructures and methods that Genovis focuses on can also
be used as carriers of various substances in the development of new drug
delivery methods. The projects are mainly in-house, but also include
collaborations with research groups, including at Lund University.

Genovis shares are listed on the First North OMX Nordic Exchange and Thenberg
Fondkommission is our certified advisor.